Targeting peptides for imaging and therapy research

Peptide Radioligand
Design and Optimization Services

Connect a target-binding peptide with the linker, labeling chemistry and biological profile your program needs.

CD ComputaBio supports cyclic and macrocyclic peptide radioligand programs through molecular design, precursor chemistry and staged experimental evaluation.

Peptide vectorLinker engineeringLabeling-unit design
DOTATOC non-metalated precursor chemical structure from PubChem CID 158782
DOTATOC (edotreotide), non-metalated precursor. PubChem CID 158782. No radiometal coordination geometry is depicted.
Home / Peptide Drug Design & Development / Peptide Radioligand Design & Optimization

Define the next discovery question

Start with a Target, a Peptide or an Existing Conjugate

A peptide radioligand combines a targeting vector with a radioactive label for molecular imaging or targeted radiation delivery. In radiometal designs, a linker connects the peptide to a chelator that coordinates the metal. The full conjugate is evaluated as a molecule: attachment chemistry can change recognition and distribution.

Our focus is the design and optimization of peptide-based constructs, particularly cyclic and macrocyclic ligands. Projects can connect discovery, precursor synthesis and nonradioactive testing with separately scoped radiochemistry and preclinical evaluation.

02 / CONJUGATE

A Validated Peptide Binder

Identify attachment-tolerant positions, compare linkers and select an appropriate labeling unit. Test whether the proposed modification preserves the recognition needed for the intended application.

03 / OPTIMIZE

An Existing Radioligand

Review the current construct and experimental profile. Nominate focused analogs to investigate loss of affinity, insufficient retention, slow clearance or unwanted normal-organ accumulation.

Next step: share your target or complete conjugate structure, available results and intended imaging or therapy objective. We will outline an appropriate starting stage.

Biology and use define the design brief

Align Target Recognition with the Intended Application

Target expression, normal-tissue distribution and extracellular accessibility guide whether a peptide can reach a useful binding site. Receptor density, ligand competition, internalization and recycling help define the assays needed after binding confirmation.

An imaging program may prioritize contrast at a particular acquisition window. A therapy program may emphasize sustained tumor-associated activity while controlling normal-tissue exposure. The preferred biological residence time is considered alongside radionuclide decay characteristics and practical study requirements.

Internalization is evaluated in context: it can support retention for some constructs, while other ligands achieve useful targeting through surface binding. The project brief sets the desired behavior before analog selection.

Design the complete construct

Co-Optimize Vector, Linker and Labeling Unit

A successful attachment position must accommodate the complete labeled format. Design reviews consider conformation, steric effects, charge and hydrophobicity together with synthesis and labeling compatibility.

Targeting peptideRecognition & selectivity
—
LinkerSpacing & property tuning
—
Labeling unitChelator + coordinated metal

Radiometal architecture shown. Radiohalogen designs use suitable direct-labeling chemistry or prosthetic groups.

A / VECTOR

Preserve Target Recognition

Use sequence–activity data, structural hypotheses and position scans to identify modifiable regions. Examine ring integrity, local flexibility and the effects of attaching a bulky or charged labeling group.

Output: candidate attachment sites and vector analogs.

B / LINKER

Tune the Connecting Chemistry

Compare spacer length, flexibility, hydrophilicity and charge using matched analogs. Stable linkers provide a baseline; cleavable motifs are considered only when a specific biological release hypothesis can be tested.

Output: a focused linker comparison matrix.

C / LABELING UNIT

Match Chemistry to the Nuclide

Select chelator candidates around metal coordination, complex stability and feasible labeling conditions. Temperature, acidity and handling requirements must be compatible with the peptide and precursor.

Output: a labeling-unit shortlist and compatibility review.

D / FULL CONJUGATE

Retest the Integrated Molecule

Compare the parent peptide, precursor and appropriate metal-loaded or labeled forms. Adding a chelator or changing the metal can alter affinity and physicochemical behavior, so each comparison retains its chemical context.

Output: experimentally testable construct hypotheses.

Design Imaging and Therapy Variants Deliberately

Related imaging and therapeutic constructs can share a targeting peptide while differing in metal, coordination geometry or labeling unit. Even when two isotopes of the same element support a matched pair, preparation, activity level and measurement window remain part of the comparison. For different elements, the chemical change is explicitly included in the evaluation plan.

Keep Peptide Mass in the Comparison

Molar activity and the total peptide amount can influence receptor occupancy and apparent uptake. Comparisons therefore preserve the relevant mass and activity information rather than attributing every difference to the linker or chelator. A stable-isotope complex helps investigate chemistry and binding, while the radioactive form is evaluated for label integrity and time-dependent performance.

Conceptual matched-linker comparison with labeled modules; no molecular structures or experimental data
Conceptual matched-linker comparisons. Boxes denote design modules, not chemical structures; specific conjugates require complete structural definitions.

Small chemical changes, whole-molecule consequences

Build Informative Conjugate Series

Initial panels isolate design variables where possible. For example, a linker-length series can keep the peptide and chelator constant, followed by a separate attachment-site comparison. Combining changes is most informative after individual effects are understood.

Polarity and charge adjustments are explored alongside target recognition and sample behavior. The objective is a useful distribution profile, supported by experiments rather than a single calculated descriptor. A nominated panel also includes the parent or another agreed reference, so each new construct has a meaningful baseline. Assay conditions and chemical forms remain attached to the data during SAR analysis.

Our cyclic peptide lead optimization services connect these conjugate comparisons with residue-level SAR, stability and synthetic feasibility.

From designed construct to qualified material

Connect Precursor Synthesis with Staged Testing

Material stageCore workDecision supported
Peptide & conjugate precursorDefined synthesis, cyclization, site-specific attachment, purification and chemical characterization.Is the intended construct available with suitable identity and quality?
Nonradioactive metal complexAppropriate stable-isotope complex preparation and analytical or binding comparisons.How does metal loading affect the construct?
Radiolabeled research materialProject-specific labeling, separation and radioanalytical evaluation through an agreed facility.Does the selected format meet the study's radiochemical requirements?

Precursor Quality

HPLC and LC-MS support purity and mass assessment. Additional methods may be needed for connectivity, isomers or metal-complex characterization. Sample concentration, counterions, solubility and storage records support meaningful comparisons.

Radiochemical Quality

Radio-HPLC or suitable radio-TLC, identity checks and stability studies address the radioactive species. Chemical purity, radiochemical purity, radionuclidic purity and molar activity describe different attributes and are reported with their measurement conditions.

Radiolabeling, isotope sourcing and in vivo modules are defined around the selected radionuclide, facility capability and study plan. Nonradioactive characterization informs design; labeled-material studies establish the radioligand's experimental profile.

Build evidence in the order decisions require

Measure Recognition, Stability and Cellular Behavior

01

Binding & Specificity

Compare parent and conjugated forms using suitable biochemical, biophysical or cellular assays. Target-positive, target-negative and blocking controls help assess target-associated recognition.

02

Uptake & Retention

Evaluate time-dependent cell association, internalized fractions or washout where relevant. Interpret results alongside receptor expression, assay format and the applied peptide mass.

03

Stability & Label Integrity

Assess relevant formulation and biological matrices. Distinguish peptide degradation, label loss and radiolysis-related changes using appropriate separation and detection methods.

Matched conditions, repeated measurements and traceable batch identity support prioritization. Binding affinity, inhibitory activity and cellular uptake are separate endpoints; each contributes to the final construct profile.

Optimize the contrast and exposure window

Balance Tumor Delivery with Normal-Tissue Clearance

Biodistribution optimization weighs target accumulation and retention against blood-pool activity and organ exposure. Kidney, liver and marrow considerations depend on the construct and study objective. Increasing circulation time is evaluated as a tradeoff, not a universal improvement.

What Should Improve?

  • Target-associated uptake at relevant time points.
  • Tumor-to-blood or tumor-to-organ contrast.
  • Retention compatible with the imaging or therapy window.
  • Clearance of non-target-associated radioactivity.

What Can Be Changed?

Linker composition, charge distribution, hydrophobicity and peptide stability provide testable design variables. Albumin-binding modifications may extend exposure, but also require evaluation of background activity and normal-organ residence.

Renal handling is assessed empirically. A charge or linker change cannot be assumed to reduce kidney retention across different peptide series. Proposed modifications are linked to a specific comparison and sampling plan.

Connect Distribution to the Right Measurement

Time-resolved tissue data, imaging and metabolite analysis can help explain a lead's behavior. Report injected activity and peptide amount, molar activity, sampling times and decay-correction conventions. Dosimetry planning additionally needs suitable time–activity information and model assumptions.2

Published molecular-design example

Study the Peptide, Chelator and Linker Together

A published TOC-based study compared changes in cyclization, lead-specific chelator chemistry and PEG spacer length. The program then evaluated recognition, cellular uptake and in vivo distribution to identify a construct for further study.1

The structural comparison illustrates why optimization should retain full chemical definitions. It is a literature example of an experimental design strategy; candidate selection for a new program follows its own target, labeling system and biological data.

Published structural comparison of TOC-derived conjugates with changes in cyclization, chelator and PEG linker
TOC-derived conjugates exploring cyclization, chelator composition and PEG spacer variation.1

A staged research program

Move from Design Brief to Prioritized Conjugates

01 / SCOPE

Define the Objective

Review target biology, ligand evidence and the intended use.

Decision: entry stage and success criteria.
02 / DESIGN

Nominate Constructs

Choose vector edits, attachment sites and labeling-unit options.

Decision: a focused comparison matrix.
03 / MAKE

Prepare & Qualify

Synthesize precursors and complete agreed material checks.

Decision: compounds ready for testing.
04 / EVALUATE

Measure Performance

Connect binding and stability with contracted radiochemical or distribution studies.

Decision: the supported candidate profile.
05 / REFINE

Rank & Iterate

Integrate results and identify the next informative changes.

Decision: redesign or progress a series.

The project proposal specifies analog counts, material quantities, assays, radiochemistry responsibilities and iteration rounds. Each review point connects a result to the next design or experimental action.

A traceable package for multidisciplinary review

Receive Defined Constructs and Decision-Relevant Evidence

✓

Target & Program Assessment

Biological objective, starting evidence, study priorities and the proposed development path.

✓

Conjugate Design Matrix

Complete chemical definitions, attachment sites, linker variants, labeling units and design rationale.

✓

Synthesis & Material Records

Agreed samples, batch identifiers, analytical results and relevant handling information.

✓

Binding & Stability Results

Contracted assay data, controls and conditions connected to each chemical form.

✓

Radiochemistry & Distribution Data

Where contracted, labeling records, radioanalytical results and preclinical study outputs.

✓

Prioritization & Next Steps

Integrated ranking, unresolved evidence gaps and recommendations for the next experimental round.

For broader optimization of the peptide scaffold, continue into cyclic peptide lead optimization. For structural interpretation, explore cyclic peptide modeling.

Planning your project

Frequently Asked Questions

Can you start with a target rather than a known peptide?

Yes. The initial scope can assess the target and define a ligand-discovery route. Conjugate design follows suitable binding evidence and chemical definition.

Can you optimize an existing peptide radioligand?

Yes. Share the complete structure, labeling information and available biological data. These identify the most useful matched analog comparisons.

How is the chelator selected?

Selection considers the intended radiometal, complex stability, labeling compatibility and whole-conjugate properties. The design is evaluated in the relevant chemical form.

Can imaging and therapy variants use the same peptide?

A common vector can be explored, but changing the metal or labeling system may alter properties. Comparative characterization is included when planning related variants.

Are radiolabeling and animal studies included?

These are separately scoped modules. The proposal identifies the selected radionuclide, facility arrangements, study endpoints and deliverables.

Can half-life extension be part of optimization?

Yes, when it supports the application. Extended exposure is assessed alongside contrast, tumor retention and normal-organ residence.

Design the next useful comparison

Bring Your Target or Conjugate.
Define Your Radioligand Plan.

Share the full structure or target, intended application, preferred labeling system and the main performance gap. We will help define the design, synthesis and experimental scope.

Send structures and supporting data to contact@computabio.com.

References

  1. Lee, D.; Li, M.; Liu, D.; et al. Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging 2024, 51, 1147–1162. doi:10.1007/s00259-023-06494-9. Figure 1 reproduced under CC BY 4.0.
  2. International Atomic Energy Agency. Guidance for Preclinical Studies with Radiopharmaceuticals. IAEA Radioisotopes and Radiopharmaceuticals Series No. 8, Vienna, 2023. IAEA publication.

Online Inquiry

Submit your project details below, and our team will respond within 24 hours.

x
Need help getting the data you need?

Talk to our technical team about your project!

I Want To Talk